Paper Details

  1. Home
  2. Paper Details

Intrathecal effects of daclizumab treatment of multiple sclerosis.

Author: BielekovaB, BlevinsG, HermanM L, MartinR, McFarlandH, OhayonJ, RichertN, WaldmannT A

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., IntramuralFunding provided by the NIH for research projects within the NIH.

Overview

This study investigated the effects of daclizumab, a humanized monoclonal antibody against CD25, on contrast-enhancing lesions (CEL) in patients with relapsing-remitting multiple sclerosis (RRMS).
Paper Details　
Original Abstract of the Article :
We previously reported that daclizumab, a humanized monoclonal antibody against CD25, reduced contrast-enhancing lesions (CEL) in patients with multiple sclerosis (MS) who were suboptimal responders to interferon-β and that this response correlated with expansion of CD56(bright) NK cells. These data...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3246406/

データ提供：米国国立医学図書館（NLM）

Daclizumab: A New Oasis in the Desert of Multiple Sclerosis

The desert of multiple sclerosis (MS) is a challenging landscape, often characterized by unpredictable relapses and progressive neurological decline. This research explores the potential of daclizumab, a humanized monoclonal antibody, to provide a new oasis of hope for patients with MS. It's like discovering a hidden spring in the desert, offering a source of life-giving relief for those enduring the harsh conditions.

Finding Relief in the Desert

The study investigates the effects of daclizumab on the intrathecal immune system, the body's defense system within the spinal cord. It suggests that daclizumab may reduce lesions in the brain and spinal cord, potentially slowing the progression of MS. It's like finding a way to replenish the dwindling water reserves in the desert, offering a chance for those suffering from MS to survive and thrive.

Hope for a Brighter Future

This research offers hope for a more effective treatment for MS. Further studies are needed to fully understand the potential of daclizumab, but it presents a promising avenue for alleviating the suffering caused by this debilitating disease. It's like finding a new path through the desert, offering a chance for those living with MS to navigate this challenging landscape with greater ease and hope.

Dr.Camel's Conclusion

This study explores the potential of daclizumab as a treatment for multiple sclerosis. While further research is needed, the findings suggest that it may offer a new and promising approach to combating this complex and challenging disease. It's like finding a hidden oasis in the desert, offering hope for a more manageable and fulfilling journey for those living with MS.
Date :
  1. Date Completed 2012-01-10
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

22076546

DOI: Digital Object Identifier

PMC3246406

Related Literature

Article Analysis
・Effects of daclizumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.